secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001104659-23-059849
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics enters up to $100M ATM equity offering through Jefferies, replacing prior $97.8M capacity
--------------------------------------------------------------------------------

- May offer and sell common stock with aggregate offering price up to $100 million via Jefferies as sales agent.
- Commission of up to 3% of gross proceeds; Jefferies will use commercially reasonable efforts.
- A&R Sale Agreement replaces original 2019 agreement; prospectus supplement filed under effective shelf registration.
- Prior remaining capacity of ~$97.8M from earlier prospectus supplements is superseded.
- Company may suspend or terminate offering at any time; shares sold at market prices under Rule 415.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/0001104659-23-059849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer